Industries > Pharma > Global Influenza Vaccines Market Outlook 2018-2028

Global Influenza Vaccines Market Outlook 2018-2028

Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other

PUBLISHED: 19 June 2018
PAGES: 138
PRODUCT CODE: PHA0318
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0318 Categories: , Tags: , , , ,

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $3.5 billion in 2018.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain’s new study tells you and tells you NOW.

In this brand new 138-page report you find 63 in-depth tables, charts and graphs – all unavailable elsewhere.

The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
Visiongain’s new investigation shows revenue predictions at overall world market, submarket, company, product and national level.

That study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies:
• Trivalent Influenza Vaccines (TIV)
• Quadrivalent Influenza Vaccines (QIV)

Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share:
• Sanofi Pasteur
• GSK
• Seqirus
• AstraZeneca
• Protein Science Corporation.
• Others

From 2018, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations’ potentials.

Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses:
• Seasonal Influenza vaccines in development
• Universal Influenza vaccines in development

The report includes forecasts to 2028 and analysis of pipeline developments for the following specific vaccines:
• Fluzone / VaxiGrip
• Seqirus
• Fluarix / FluLaval
• FluMist / Fluenz
• FluBlok
• Other

The study shows you prospects for those drug sales in developed and developing regions. There see individual revenue forecasts to 2028 for 11 countries:
• United States
• Japan
• The EU 5 – Germany, France, United Kingdom, Italy and Spain.
• Brazil, Russia, India and China

Global Influenza Vaccines Market Outlook 2018-2028

Who should read this report?
• Anyone within the influenza vaccines value chain.
• Pharmaceutical companies
• Vaccine manufacturers
• Healthcare biotech companies
• Generics and biosimilar producers
• Drug delivery companies and other technology providers
• Contract/clinical research organisations (CROs)
• Pharma contract manufacturers,
• Pharma/healthcare wholesale and distribution companies
• Medical device companies
• Healthcare diagnostics companies
• R&D specialists
• Business development managers
• Marketing managers
• Technologists
• Suppliers
• Investors
• Banks
• Government agencies
• Contractors

Visiongain’s study is intended for anyone requiring commercial analyses for the influenza vaccines market and leading companies. You find data, trends and predictions.

Buy our report today Global Influenza Vaccines Market Outlook 2018-2028: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other. Avoid missing out by staying informed – get our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Influenza Vaccines Market Outlook 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Influenza Vaccines Market Outlook 2018-2028


Latest Pharma news

Visiongain Publishes Pharmaceutical Product Information Management System Market Report 2020-2030

Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.

19 October 2020

READ

Visiongain Publishes Pulmonary/Respiratory Drug Delivery Market Report 2020-2030

The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.

12 October 2020

READ

Visiongain Publishes Real-World Evidence (RWE) Solutions Market Report 2020-2030

We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

02 October 2020

READ

Visiongain Publishes mRNA Vaccines Market Report 2021-2031

The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.

02 October 2020

READ

Categories

Category